The Chicago Entrepreneur

Amgen’s rare-disease treatment biosimilar Bkemv gets FDA approval

Pharmaceutical regulators approved Amgen’s Bkemv, a biosimilar to rare-disease treatment Soliris.

Previous post Hess shareholders approve Chevron’s $53 billion acquisition bid
Next post New Jersey to get $125 million from Orsted after offshore wind projects halted